levodopa has been researched along with pyrazines in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (33.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Andreeva, NI; MashkovskiÄ, MD | 1 |
Jing, FC; Wang, DQ; Wang, W | 1 |
Balan, G; Barreiro, G; Boscoe, BP; Chen, L; Chenard, LK; Cianfrogna, J; Claffey, MM; Coffman, KJ; Drozda, SE; Dunetz, JR; Fonseca, KR; Galatsis, P; Grimwood, S; Lazzaro, JT; Mancuso, JY; Miller, EL; Reese, MR; Rogers, BN; Sakurada, I; Shaffer, CL; Skaddan, M; Smith, DL; Stepan, AF; Trapa, P; Tuttle, JB; Verhoest, PR; Walker, DP; Wright, AS; Zaleska, MM; Zasadny, K; Zhang, L | 1 |
3 other study(ies) available for levodopa and pyrazines
Article | Year |
---|---|
[The pharmacologic basis of the antidepressive activity of the new psychotropic preparation pyrazidol].
Topics: 5-Hydroxytryptophan; Acetylcholine; Amphetamine; Animals; Antidepressive Agents; Arecoline; Blood Pressure; Cats; Dogs; Drug Synergism; Epinephrine; Gastrointestinal Motility; Hexobarbital; Indoles; Levodopa; Nicotine; Norepinephrine; Phenethylamines; Pyrazines; Rabbits; Rats; Reserpine; Tryptamines | 1975 |
[Effects of tetramethylpyrazine on brain oxidative damage induced by intracerebral perfusion of L-DOPA in rats with Parkinson's disease].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Catechols; Chromatography, High Pressure Liquid; Corpus Striatum; Hydroxybenzoates; Levodopa; Male; Microdialysis; Oxidative Stress; Oxidopamine; Parkinson Disease, Secondary; Pyrazines; Random Allocation; Rats; Rats, Sprague-Dawley | 2007 |
Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Allosteric Regulation; Animals; Antiparkinson Agents; Biological Availability; Cell Membrane Permeability; Dogs; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Hypersensitivity, Delayed; Levodopa; Macaca fascicularis; Madin Darby Canine Kidney Cells; Male; Microsomes, Liver; Models, Molecular; Parkinson Disease; Pyrazines; Pyrazoles; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Structure-Activity Relationship | 2014 |